Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PSDV recovered pretty well to 1.65 now. Looks like large seller this morning...large for this low cap stock...but not huge.
ATRS breakout today, up 7%, leaving base in high 3's, now 4.25.
PSDV seems like shakeout...as low as 1.45, reversed to 1.58.
No news I see. Volume fairly high.
PSDV 1.65 down on no news...low floater, low market cap (35M) low float with approved drug delivery device. Device is inserted in eye.
Several EU approvals. Has pending NICE (British regulatory agency) meeting October 11, to look at cost.
Financing/dilution was done recently, so good cash position (16M, no debt, does generate revenue)
Will post more dd and links. but heads up on price drop today. Great long term value here...imo.
http://investors.psivida.com/releasedetail.cfm?ReleaseID=704554
upcoming earnings and conference call September 24.
http://investors.psivida.com/releasedetail.cfm?ReleaseID=707320
Recent company presentation...
http://www.veracast.com/webcasts/stifel/healthcare2012/92110532.cfm
gl
I guess its easier for me to give this kind of advice since I was never long NAVB. Nothing against it, just missed it at what I thought was a good price.
I actually got caught long EXEL when they diluted, and held most and added some, so I get that side of it.
I was planning to go short NAVB on approval, (figuring some kind of "sell the news") and I established a bear call spread last week. I was expecting approval with temporary spike then slow bleed. I got lucky with the CRL and got instant and bigger profits. For now, my money is on a slow sell off over the next few days/weeks. Hopefully, and probably, longs will be fine over the medium to long term. And more importantly, hopefully patients will ultimately benefit from their technology.
NAVB my opinion traders will lose interest here in the next few days/weeks. With the threat of dilution looming, no reason to hold. If I were still holding, I would look for a graceful exit as soon as possible. Too many other good plays out there with catalysts.
Maybe revisit after dust settles and dilution happens.
If you are adept with options, makes for a good short via puts.
I just wouldn't want to hold it and watch it bleed.
NAVB What about their cash position? Won't they need to dilute soon?
thanks for posting chart...and thanks to ryman for better link...
ATRS 3.87 presentation from few days ago. Vibex MTX data due next month, NDA filing either early next year, or late this year.
How to post chart? Nice base in the 3.80-3.90 range. This ran way up in July, due imo largely to Nasdaq uplisting.
Deep pipeline here. Good revenue, company is essentially break-even with good cash position and no debt. I like its chances for a break to the upside in anticipation of Vibex MTX/auto injector combo data.
http://finance.yahoo.com/news/antares-pharma-present-stifel-nicolaus-110000216.html
VNDA 4.14 trading below cash value, with upcoming catalysts.
This one may have (finally) found a bottom.
http://seekingalpha.com/article/656601-vanda-pharma-trading-below-cash-with-upcoming-catalysts-expected-2h12
VNDA 4.01 113M market cap, cash on hand 157M, no debt with upcoming catalysts.
http://seekingalpha.com/article/656601-vanda-pharma-trading-below-cash-with-upcoming-catalysts-expected-2h12
Looking to see if $4.00 can hold. That cash value should act as a magnet for market cap.
NVIV 2.45 up +16% on 4 times average volume.
I think this report aired today on FOX and Friends this morning (Fox News channel morning magazine ala Today)
http://video.foxnews.com/v/1704194608001/new-hope-for-paralysis/
ATRS 3.48 breaking out.
Formerly AIS (moved to Nasdaq from AMEX last week)
Strong pipeline, on verge of profitability, described as "biotech for widows and orphans".
I think this is long term multi-bagger or (more likely) gets bought out within next year or two.
AIS on amex now, to change to nasd June 15 with new ticker symbol, ATRS.
Its had quite a nice run this month from low of 2.60 to 3.28 now.
http://finance.yahoo.com/news/antares-transfers-listing-nasdaq-nyse-142536369.html
THLD 6.28 I like the chart. Looks stable here.
Annual shareholder meeting this week (5/17) could bring some attention to this one.
Two ASCO posters also.
ACAD 1.63 Share price moving up after 4-5 week consolidation/basing period.
Pivotal phase data release expected by end of September.
XNPT $5.23 breaking out above 200dma
HZNP $3.55 Very low float...moves quickly when it moves.
Great buying opp right here, imo.
MNOV...3.25 low float popping today
http://seekingalpha.com/article/554951-this-developmental-pharma-has-potential-to-be-a-long-term-multibagger
AIS nice no-hype summary of their story in this article.
Gotta like the revenue growth.
http://seekingalpha.com/article/545141-winners-and-losers-in-the-deadly-waters-of-biotech-investing?source=yahoo
ACAD no PDUFA, but pivotal phase III data due end of September. I think with their study redesigned, it should see a significant move late summer.
AIS ...$3.20 more epipen settlement details in this article.
"Under a separate agreement, Teva has agreed to provide Antares with device orders of an undisclosed amount in the years 2013 and 2014, to make a milestone payment to Antares upon FDA approval of epinephrine auto-injector, and to assume all litigation costs related to the patent litigation between Teva and Meridian Medical."
http://www.marketwatch.com/story/antares-pharma-announces-epinephrine-auto-injector-settlement-agreement-between-teva-and-pfizer-2012-04-26
Also announcement of launch of OAB treatment "gelnique" with Watson...
http://finance.yahoo.com/news/watson-antares-announce-introduction-gelnique-110000196.html
AIS.. $3.25 gap up on epipen settlement news.
http://finance.yahoo.com/news/antares-pharma-announces-epinephrine-auto-132600665.html
..."biotech for widows and orphans"...
http://community.nasdaq.com/News/2012-04/investing-in-smallcap-stocks-anomalies-are-golden.aspx?storyid=131718
AIS 3.07 This stock doesn't have wild swings, but strong move up today.
New patent granted yesterday. No news release from company. Question is, which drug/partner will go with this injector?
http://www.freepatentsonline.com/8162886.html
PSDV $2.43 benefits from this news also.
ACAD $1.48 high volume bounce off of 200 dma.
ACAD 1.48 presentation tomorrow at 11:00 am, to be broadcast live via webcast.
http://phx.corporate-ir.net/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=1682900
Stock has corrected after Seeking Alpha pump article last month.
Phase III data due Q3 (September).
NOTE open interest in September options: 4392 2.5 calls versus 2571 2.5 puts.
AMRN Ok, here's your 9.40's...
AIS $3.17 This stock is quietly holding its recent gains, even with some market weakness. One of my favorites for a long term holding.
AMRN $10.16 and changing. Doesn't pay to be timid with this stock.
ACAD $2.03, up 18% Zack's J Napodano released his analysis on his twitter account.
http://scr.zacks.com/Theme/Zacks/files/March%206,%202012_ACAD_Will%20Third%20Time%20Be%20A%20Charm%20For%20Acadia%20Pharmaceuticals_Napodano_v001_i7ej43.pdf
Also new seeking alpha "in focus" report released yesterday.
http://seekingalpha.com/article/427681-acadia-pharmaceuticals-could-be-another-ariad
AIS webcast with presentation.
http://wsw.com/webcast/cowen6/ais/
AIS Cup and handle breakout?
Author references it in his article. Seems to be happening now.
http://seekingalpha.com/article/411511-4-biopharma-swing-trades-for-the-mid-term
AIS 2.92 now, multi-year high.
Earnings due Monday.
http://seekingalpha.com/article/416361-near-term-stock-catalysts-for-these-bio-pharmas
Also, buyout speculation based on recent hire.
http://seekingalpha.com/article/411511-4-biopharma-swing-trades-for-the-mid-term
$NGSX One of sheff's competitors (with large following) sold for something like a 7% profit.
Just a blip, IMO.
$NGSX back to very low volume now that "sheff effect" has subsided?
HOGS $9.70 breakout this morning, no news that I know of.
Still undervalued by nearly any fundamental measure.
HOGS ($8.41) similar story. Also China pork company. Fundamentals are great, but many don't trust numbers from China. If their numbers are right, its severely undervalued. Had fairly large insider buys late August in 7.90-8.12 range.
http://finance.yahoo.com/q/it?s=HOGS+Insider+Transactions
Shorts have had their way with it for months. Have they covered and gone away?
AMLN FDA approves new use for BYETTA.
http://biz.yahoo.com/e/111020/amln8-k.html
I'm looking for an opportunity to buy after sell-off. Another PDUFA date 1/28/12.